Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Finlay, Darren ^a   Richardson, Robyn D ^a   Landberg, Lisa K ^a   Howes, Amy L ^a   Vuori, Kristiina ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; AMMONIUM PYRROLIDINEDITHIOCARBAMATE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MALONALDEHYDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ARTIFACT; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; FALSE POSITIVE RESULT; HIGH THROUGHPUT SCREENING; POINT MUTATION; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; SENSITIVITY ANALYSIS; WILD TYPE; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; HUMANS; POINT MUTATION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78149460691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013375     Document Type: Article

References (23)

1. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med 5: 157-163.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
3. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Disc 7: 1001-1012.
4. LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75.
5. Boldin MP, Goncharov TM, Goltsev YV, Wallach D (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815.
6. Mellier G, Huang S, Shenoy K, Pervaiz S (2010) TRAILing death in cancer. Mol Aspects Med 1: 93-112.
7. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, et al. (2001) Sensitization for death receptor- or drug-induced apoptosis by reexpression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877.
8. Mühlethaler-Mottet A, Balmas K, Auderset K, Joseph JM, Gross N (2003) Restoration of TRAIL-induced apoptosis in a caspase-8-deficient neuroblastoma cell line by stable re-expression of caspase-8. Ann N Y Acad Sci 1010: 195-199.
9. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535.
10. Finlay D, Vuori K (2007) Novel Non-catalytic Role for Caspase-8 in Promoting Src Mediated- Adhesion and Erk Signaling in Neuroblastoma Cells. Cancer Res 67: 11704-11711.
11. Zhang Y, Yoshida T, Zhang B (2009) TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther 8: 917-922.
12. Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, et al. (2003) TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 13: 539-553.
13. Jin CY, Park C, Moon SK, Kim GY, Kwon TK, et al. (2009) Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20: 713-722.
14. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S (2001) Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol 81: 380-390.
15. Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB (2002) Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52: 1-11.
16. Huang L, Xu J, Li K, Zheng MH, Kumta SM (2004) Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone. Bone 34: 971-981.
17. Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, et al. (2009) A cellbased high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol. Immunother 58: 1229-1244.
18. Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, et al. (2009) TRAILinduced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15: 5924-5935.
19. Moxley KM, Chengedza S, Benbrook DM (2009) Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol 115: 438-442.
20. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, et al. (2003) YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1. J Natl. Cancer Inst 95: 516-525.
21. Bradford M (1972) Protein assay based on coomassie stain. Anal Biochem 72: 248.
22. Finlay D, Howes A, Vuori K (2009) Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res 69: 5023-5029.
23. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.